

Financial news for RTRX dated on 2020-06-08: Retrophin Announces Proposed Public Offering of Common Stock; No Terms Disclosed

Financial news for RTRX dated on 2020-05-12: BMO Capital Maintains Outperform on Retrophin, Raises Price Target to \$34

Financial news for RTRX dated on 2020-05-11: Retrophin Q1 Adj. EPS \$(0.200) Beats \$(0.670) Estimate, Sales \$47.800M Beat \$43.430M Estimate

Financial news for RTRX dated on 2020-03-09: Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Financial news for RTRX dated on 2020-02-25: Barclays Downgrades Retrophin to Equal-Weight, Announces \$19 Price Target

Financial news for RTRX dated on 2020-02-24: Retrophin Q4 EPS \$(0.70) Misses \$(0.64) Estimate, Sales \$46.688M Beat \$46.02M Estimate

Financial news for RTRX dated on 2020-01-13: Retrophin Sees Q4 Net Product Sales of \$47M

Financial news for RTRX dated on 2019-10-30: Retrophin Q3 EPS \$(0.66) Beats \$(1.05) Estimate, Sales \$44.4M Miss \$45.3M Estimate

Financial news for RTRX dated on 2019-08-23: Canaccord Genuity Maintains Buy on Retrophin, Lowers Price Target to \$23

Financial news for RTRX dated on 2019-08-23: BMO Capital Maintains Outperform on Retrophin, Lowers Price Target to \$33

Financial news for RTRX dated on 2019-08-23: Barclays Maintains Overweight on Retrophin, Lowers Price Target to \$20

Financial news for RTRX dated on 2019-08-23: Nomura Maintains Buy on Retrophin, Lowers Price Target to \$33

Financial news for RTRX dated on 2019-08-22: Retrophin shares are trading lower after the company reported its Phase 3 FORT study of Fosmetpantotenate did not meet its primary or secondary endpoints.

Financial news for RTRX dated on 2019-08-22: Retrophin's Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN Did Not Meet its Primary or Secondary Endpoints

Financial news for RTRX dated on 2019-08-06: Retrophin Q2 EPS \$(0.58) Beats \$(0.64) Estimate, Sales \$44.707M Beat \$43.01M Estimate

Financial news for RTRX dated on 2019-06-28: Retrophin Announces FDA Approval Of THIOLA EC 100mg And 300mg Tablets For The Treatment Of Cystinuria

Financial news for RTRX dated on 2019-06-18: Retrophin Announces Cooperative Research And Development Agreement With NCATS And Alagille Syndrome Alliance To Identify Potential Therapeutics For Alagille Syndrome

Financial news for RTRX dated on 2019-05-07: Retrophin Announces Top-Line Results From Pivotal Phase 3 Fort Study In Pkan On-Track For 3Q 2019; Announces Enrollment Ongoing In Phase 3 Clinical Trials Of Sparsentan For Patients With Rare Nephropathies Fsgs And Igan

Financial news for RTRX dated on 2019-05-07: Retrophin Q1 EPS \$(0.63) Misses \$(0.59) Estimate, Sales \$39.6M Miss \$40.99M Estimate

Financial news for RTRX dated on 2019-04-22: Barclays Initiates Coverage On Retrophin with Overweight Rating, Announces \$36 Price Target

Financial news for RTRX dated on 2019-02-27: Retrophin shares are trading higher after the company beat Q4 EPS estimates.

Financial news for RTRX dated on 2019-02-26: Retrophin Q4 EPS \$(0.21) Beats \$(0.48) Estimate, Sales \$43.77M Miss \$44.53M Estimate

Financial news for RTRX dated on 2019-02-12: UPDATE: Canaccord Genuity On Retrophin 'Sees 1H19 proof-of-concept data for CNSA-001 in PKU patients, (2) April'19 data from SONAR study of atrasentan in diabetic nephropathy, and (3) June 30 PDUFA for a new formulation of Thiola' As Catalysts In 1H19

Financial news for RTRX dated on 2019-02-12: Canaccord Genuity Views 'recent weakness in RTRX shares as offering an attractive buying opportunity into several 1H19

catalysts'; Maintains Buy, \$36 Target

Financial news for RTRX dated on 2019-01-28: Stocks Which Set New 52-Week Low Mon., Jan. 28, 2019

Financial news for RTRX dated on 2019-01-07: Retrophin Sees 2019 Product Sales of \$164M

Financial news for RTRX dated on 2019-01-03: Retrophin Names Eric Dube President And CEO

Financial news for RTRX dated on 2018-12-27: Retrophin Reports Dosing Of First Patient In Pivotal Phase 3 PROTECT Study Of Sparsentan For Treatment Of IgA Nephropathy

Financial news for RTRX dated on 2018-12-20: Retrophin Completes Enrollment Of Pivotal Phase 3 FORT Study Of Fosmetpantotenate In PKAN

Financial news for RTRX dated on 2018-11-19: UPDATE: Nomura Recommends 'owning RTRX into 3 potentially positive data FY19 readouts starting in 1H19 that may support 3 approvals over the next 2 years'

Financial news for RTRX dated on 2018-11-19: Nomura Initiates Coverage On Retrophin with Buy Rating, Announces \$57 Price Target

Financial news for RTRX dated on 2018-11-12: Retrophin Announces FDA Acceptance of its New Drug Application for Thiola in the Treatment of Cystinuria

Financial news for RTRX dated on 2018-11-01: Retrophin Q3 EPS \$(0.68) Misses \$(0.46) Estimate, Sales \$40.706M Miss \$44.42M Estimate

Financial news for RTRX dated on 2018-10-30: Jefferies Initiates Coverage On Retrophin with Buy Rating, Announces \$44 Price Target

Financial news for RTRX dated on 2018-10-25: Retrophin Reports Publication Of Phase 2 DUET Study Of Sparsentan For Treatment Of Focal Segmental Glomerulosclerosis In Journal Of American Society Of Nephrology

Financial news for RTRX dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for RTRX dated on 2018-08-17: Canaccord Genuity Initiates Coverage On Retrophin with Buy Rating, Announces \$36 Price Target

Financial news for RTRX dated on 2018-07-30: Retrophin Names Noah Rosenberg CMO

Financial news for RTRX dated on 2018-07-26: Retrophin CEO Stephen Aselage To Retire, Will Remain In His Role Until A Replacement Is Appointed

Financial news for RTRX dated on 2018-07-26: Retrophin Q2 Adj. EPS \$(0.25) Beats \$(0.35) Estimate, Sales \$41.3M Miss \$43.22M Estimate

Financial news for RTRX dated on 2018-06-14: Retrophin Reports US PTO Issued New Patent Covering Co.'s Product Candidate Sparsentan

Financial news for RTRX dated on 2018-06-04: Retrophin Reports Independent Data Monitoring Committee's Review Of Safety Data Supports Continuing With Current Phase 3 FORT Study As Planned, Top-Line Data Due Second Half Of 2019

Financial news for RTRX dated on 2018-05-01: Retrophin Reports Q1 2018 EPS of -0.14 vs -0.45 Est Revenue of \$38.4M vs \$39.32M Est

Financial news for RTRX dated on 2018-04-03: Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis

Financial news for RTRX dated on 2018-02-27: Retrophin Reports Q4 Adj. EPS \$0.07 vs \$(0.19) Est., Sales \$42.2M vs \$41.7M Est.

Financial news for RTRX dated on 2018-01-08: Retrophin Sees Q4 Sales ~\$42M vs \$41.7M Est., Prelim. FY17 Sales ~\$155M vs \$154M Est.,

Financial news for RTRX dated on 2018-01-05: Retrophin, Censa Pharma Report Strategic Collaboration To Advance CNSA-001 For treatment Of PKU

Financial news for RTRX dated on 2017-11-07: Retrophin Reports Q3 EPS \$(0.46) vs \$(0.25) Est., Sales \$40.3M vs \$40.5M Est.

Financial news for RTRX dated on 2017-10-05: Retrophin Announces Child Neurology Society Presentation Includes Data Suggesting 30-Month Treatment With

Fosmetpantotenate Was Associated With Persistent Improvement In Patient Functioning

Financial news for RTRX dated on 2017-09-05: Retrophin Announces a Cooperative Research and Development Agreement with NCATS and NGLY1.org to Identify Potential Small Molecule Therapeutics for NGLY1 Deficiency

Financial news for RTRX dated on 2017-08-09: Retrophin Reports Q2 Adj. EPS \$0.03 vs \$(0.22) Sales \$38.8M vs \$37.36M

Financial news for RTRX dated on 2017-07-25: Retrophin Begins Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN

Financial news for RTRX dated on 2017-06-01: Retrophin Reports Expansion of IP Estate for Sparsentan; Received New Patents in US, Europe

Financial news for RTRX dated on 2017-06-01: Retrophin Reports Increase Of IP Estate For Sparsentan With Newly Issued Patents In U.S., Europe

Financial news for RTRX dated on 2017-05-04: Retrophin Reports Q1 Adj. EPS \$0.01 vs \$(0.26) Est., Sales \$33.62M vs \$36.2M Est.

Financial news for RTRX dated on 2017-04-06: William Blair Initiates Coverage On Retrophin With Outperform

Financial news for RTRX dated on 2017-03-03: 8-K from Ligand Pharma Highlights Co. is Eligible to Receive \$1.6M Upon Initiation of Retrophin's Phase 3 Trial of Sparsentan, ~\$5.99M Upon Filing of NDA in FSGS, Potential Net Milestones of \$65M+ in the Future, 9% Net Royalties

Financial news for RTRX dated on 2017-03-01: TheStreet's Adam Feuerstein Tweets '\$RTRX Sparsentan ph3 study will include interim analysis of proteinuria, which if +, can serve as accelerated approval endpoint. Compromise.'

Financial news for RTRX dated on 2017-03-01: Martin Shkreli Comments on Retrophin: 'Retrophin is so poorly run. Steve Aselage has no idea what he is doing. I can't believe I let this guy steal my company from underneath my feet. What a loser.'

Financial news for RTRX dated on 2017-03-01: Retrophin Reports Q4 Non-GAAP EPS \$0.00 vs. YoY \$0.06 Sales \$37.32M vs. \$35.95M Est.

Financial news for RTRX dated on 2017-03-01: Retrophin Says Phase 3 Trial Of sparsentan To Start In 2H 2017

Financial news for RTRX dated on 2017-01-09: Retrophin Sees Q4 Rev. ~\$37M vs. Est. \$35.9M, FY17 Rev. ~\$134M vs. Est. \$132M

Financial news for RTRX dated on 2016-04-12: BMO Capital Initiates Coverage on Retrophin at Outperform, Announces \$25.00 PT

Financial news for RTRX dated on 2016-01-11: Retrophin Sees FY2015 Sales \$99.90M vs \$98.90M Est

Financial news for RTRX dated on 2015-11-02: JMP Securities Initiates Coverage on Retrophin at Market Outperform, Announces \$30.00 PT

Financial news for RTRX dated on 2015-05-15: Avondale Partners Initiates Coverage on Retrophin at Outperform, Announces \$39.00 PT

Financial news for RTRX dated on 2015-04-28: Deutsche Bank Initiates Coverage on Retrophin at Buy, Announces \$50.00 PT

Financial news for RTRX dated on 2015-04-02: Leerink Swann Initiates Coverage on Retrophin at Outperform, Announces \$48.00 PT

Financial news for RTRX dated on 2015-03-30: Nomura Initiates Coverage on Retrophin at Buy, Announces \$31.00 PT

Financial news for RTRX dated on 2015-01-09: Retrophin Reports Prelim FY2014 Sales \$28.30M, Announces Sparsentan Wins Orphan Drug Designation

Financial news for RTRX dated on 2014-08-12: Retrophin Reports Q2 EPS of \$(0.52)

Financial news for RTRX dated on 2014-07-28: UPDATE: Retrophin Announces Bid to Acquire Clinuvel Pharmaceuticals

Financial news for RTRX dated on 2014-05-29: Retrophin Sees FY2015 EPS \$0.75-1.25; Raises FY2015 Sales Guidance from \$36.0M-41.0M to \$60.0M-70.0M

Financial news for RTRX dated on 2014-05-29: Retrophin Raises FY2014 Sales Guidance

from \$20.0M-22.0M to \$30.0M-35.0M vs \$20.0M Est

Financial news for RTRX dated on 2014-05-12: Retrophin Initiates Global Access for RE-024 in Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Financial news for RTRX dated on 2014-03-27: Retrophin Reports FY EPS of \$(2.38)

Financial news for RTRX dated on 2014-02-12: Retrophin Sees FY2014 Sales \$10.0M-12.0M, Sees FY14 Sales \$19-21M

Financial news for RTRX dated on 2013-12-17: Transcept Pharmaceuticals Statement on the Withdrawal of Retrophin's \$4.00/Share Offer

Financial news for RTRX dated on 2013-12-17: Retrophin Unveils New Clinical Development Candidate RE-034, An ACTH Analog

Financial news for RTRX dated on 2013-12-12: Retrophin to Co-Sponsor Phase II Clinical Trial of Intranasal Oxytocin for Schizophrenia

Financial news for RTRX dated on 2013-12-12: Retrophin to Acquire Kyalin Biosciences

Financial news for RTRX dated on 2013-08-16: Retrophin Signs Exclusivity Agreement with Major Pharmaceutical Company to Negotiate License to a Product to be Developed for Autism and Schizophrenia